{
    "nct_id": "NCT05210790",
    "official_title": "A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients With Polycythemia Vera",
    "inclusion_criteria": "All subjects must meet ALL of the following inclusion criteria to be enrolled. There are additional inclusion criteria.\n\n* Male and female subjects aged 18 (or the country specific minimum age of consent >18) years or older.\n* Meet revised 2016 World Health Organization (WHO) criteria for the diagnosis of polycythemia vera.\n* At least 3 phlebotomies due to inadequate hematocrit control in 6 months before randomization or at least 5 phlebotomies due to inadequate hematocrit control in 1 year before randomization.\n* CBC values immediately prior to randomization:\n\n  1. Hematocrit <45%,\n  2. WBC 4000/μL to 20,000/μL (inclusive), and\n  3. Platelets 100,000/μL to 1,000,000/μL (inclusive)\n* Subjects receiving cytoreductive therapy at randomization must be on a stable PV therapy regimen.\n* Subjects treated with phlebotomy alone at randomization must have stopped cytoreductive therapy 2 to 6 months before screening.\n\nMain\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "Subjects must meet NONE of the following exclusion criteria to be enrolled. There are additional exclusion criteria.\n\n* Clinically meaningful laboratory abnormalities at Screening.\n* Subjects who require phlebotomy at hematocrit levels lower than 45%.\n* Clinically significant thrombosis (e.g., deep vein thrombosis or splenic vein thrombosis) within 2 months prior to randomization.\n* Active or chronic bleeding within 2 months prior to randomization.\n* History of invasive malignancies within the last 5 years, except localized cured prostate cancer and cervical cancer.\n* Subjects with in situ or stage 1 squamous cell carcinoma of the skin, in situ or stage 1 basal cell carcinoma of the skin, or in situ melanoma of the skin identified during screen unless the cancer is adequately treated before randomization.\n* Received Busulfan, Pipobroman or 32Phosphorus within 7 months prior to screening.",
    "miscellaneous_criteria": "Main"
}